Until the 1960s celiac disease (CD) or sprue was considered a pediatric disease that was rarely diagnosed in adulthood. Thanks to greater awareness of the disease and the availability of improved diagnostic tools (above all, sophisticated endoscopic techniques and the development of reliable serological markers), the prevalence of CD in Western countries has been increasing steadily, and it is now recognized as a common disorder, even in adults. However, many cases of this disease still go undiagnosed, especially among the elderly and in patients with atypical clinical presentations (which are by no means uncommon). On the other hand, the frequency of unfounded diagnoses of CD is also on the rise. This reflects a tendency toward exclusively symptomatic diagnosis as well as the growing use of invalidated tests for CD (e.g., the cytotoxic test, the sublingual or subcutaneous provocation/ neutralization test, etc.). As a result, public healthcare spending is being increased in several countries (Italy included) by the growing number of prescriptions for gluten-free diets. This editorial discusses the problems of under-and over-diagnosis of CD and provides an algorithm for management of suspected cases designed to minimize both problems with particular importance to morphologic aspects of small bowel (also in electron microscopy), in basal conditions or in gluten-free diets.
Celiac disease (CD) is a chronic immunemediated enteropathy induced by ingestion of gluten-containing foods. It is characterized by intestinal malabsorption and total or subtotal atrophy of the intestinal villi. The mucosal lesions affect the proximal small intestine and can extend distally for a variable distance (1) .
Until the 1950s, CD was essentially considered a pediatric disease (2) that was rarely diagnosed in adulthood (3). Since then, our understanding of its histological features has been considerably expanded by the introduction of new diagnostic tools (4) (e.g., perioral biopsy of small intestine), the increasingly widespread use of immunohistochemical techniques, and ultrastructural studies based on transmission and scanning electron microscopy. Endoscopy has facilitated the detection of the early morphological and histological alterations associated with CD, and the availability of reliable serological markers have played key roles in the increased frequency of diagnosis of CD. Greater awareness and improved diagnosis have probably contributed to the increasing prevalence of CD in Western countries, which is currently between 1:100 and 1:120 (5) (6) (7) (8) .
It is now clear that CD should be considered in patients of all ages, including the elderly, as shown by recent reports (9) (10) . However, advanced age may still function as a confounding factor, leading to underdiagnosis of this disease in older patients. In addition, clinical presentations vary widely in CD. Some forms are virtually asymptomatic; in others extraintestinal manifestations (e.g., iron-deficiency anemia, dermatitis herpetiformis, cutaneous manifestation, diarrhea and autoimmune disorders) predominate, and gastrointestinal symptoms may be completely absent. These so-called atypical . . forms are much more common than originally believed. Awareness of these forms is much more limited among patients and physicians alike, and the risk of delayed or missed diagnosis in these cases is still high.
On the other hand, the increasing awareness of the high prevalence of CD can also lead to overdiagnosis. Recent years have witnessed an increase in the frequency of symptom-based diagnosis with no serological and/or histological support. Non-specific gastrointestinal symptoms (e.g., abdominal discomfort and bloating) may seem to be related to the ingestion of gluten. Like several other food components (e.g., caffeine), gluten acts as an exorphin, and as such it can alter intestinal wall motility and the endoluminal bacterial flora (11) . Its withdrawal may therefore produce some degree of improvement in the patient's symptoms, even if the patient is not suffering from CD.
Patients with sprue have formed organizations aimed at increasing awareness of CD among the public and medical communities. Examples include the Associazione Italiana Celiachia (AIC) in Italy, the Association of European Coeliac Societies (AOECS), and the American Celiac Disease Alliance (ACDA). These associations not only provide information about the importance of a gluten-free diet (GFD) and ways to facilitate adherence, they also support the creation and diffusion of evidencebased guidelines for the diagnosis and management of the disease. The GFD is the mainstay of CD therapy, and its use can prevent several serious complications that often characterize the natural history of the disease (12), including ulcerative jejuno-ileitis, splenic hypotrophy and atrophy (13) (14) (15) , enteropathy-associated T-cell lymphoma (EATL) (16) , esophageal and oropharyngeal carcinomas, small bowel adenocarcinoma (17) (18) , collagenous and lymphocytic forms of colitis, and invasive pneumococcal infection (19) . However, CD cannot be diagnosed based solely on the presence of clinical improvement in response to a GFD.
Small-intestinal biopsy remains the gold standard for diagnosis of CD. Endoscopic identification of signs of villous atrophy in CD patients (loss or attenuation of Kerckring's duodenal folds, scalloping of the mucosal folds) was a milestone in the diagnosis of this disease (20-23). One of the major debates regarding endoscopic diagnosis of CD revolves around the optimal sites for biopsy of the duodenal mucosa. Lesion distribution may be patchy, and conventional endoscopic biopsy can be associated with sampling errors and even biopsies of incorrect sites (e.g., ileum) (24) . Over the past decade, attempts to improve the diagnostic yield of these biopsies has led to the development of several new approaches, which have been reviewed elsewhere (25) . They include chromoendoscopy, computed virtual chromoendoscopy, video capsule endoscopy, and double-balloon endoscopy) (26) (27) (28) (29) (30) . Some of these procedures are performed only in specialist settings, and all are naturally more costly than conventional endoscopic biopsy. One of the simplest methods for collecting duodenal biopsies for diagnosis of CD in clinical settings is the "waterimmersion" technique (31) . Combined with highresolution magnification endoscopy, this technique exhibits good reproducibility (32) , and it is also the best approach for subjects with patchy lesions (33) and/or villous atrophy confined to the duodenal bulb (34) .
Another cornerstone in the history of CD diagnosis was the introduction of the Marsh classification (35) (and subsequent modifications to this system made by Oberhuber) (36) , which has improved the description of the mucosal lesions that characterize CD. Correct assessment -especially in the presence of early-stage lesions (Marsh type I or II) -requires at least 4-6 adequate-sized tissue samples, at least some of which must be oriented in a way that allows assessment of the villus and crypt. It is important to recall that, in the absence of villous atrophy or a reduced villus:crypt ratio, an increased number of intraepitheliallymphocytes (IELs) is less important for histological diagnosis of CD. The presence of abnonnal IELs with clonal TCRy gene rearrangements imply an increased risk for overt EATL (37) . Even when it is associated with a lymphocyte-plasma cell infiltrate along the villous axis and in the lamina propria, an increased number of IELs is not specific for CD (38) . In the presence of a leukocyte infiltrate (neutrophil or eosinophil), it is also typical of several other diseases with immunological, viral, or bacterial etiologies (39) (40) .
In our opinion, the first step in the correct interpretation of duodenal specimens should be the exclusion of other possible causes of duodenal damage (e.g., autoimmune enteropathies), a task that involves integrative assessment of clinical and histological data. When other causes have been ruled out, CD can be reliably diagnosed (and a GFD started) even in the presence of minimal lesions (e.g., Marsh type II) if anti-endomysial (EMA) and/or anti-transglutaminase (anti-tTGA) antibody titers are positive. Gluten-stimulated organ culture of biopsy specimens (41) has also proved useful in diagnosing CD.
Although serology may be helpful for the diagnosis of CD, clinicians should remember that the prevalence of EMA antibody positivity in clinical practice is lower than previously believed (42) (43) and that anti-tTG levels show better correlation with the degree of villous atrophy (44) . These considerations highlight the existence of a "grey zone" in CD characterized by seronegativity in the presence of sometimes severe villous atrophy. On the other hand, false-positive serological findings are also encountered (45) (e.g., false-positive titers of anti-gliadin antibodies in infants <18 months old).
For these reasons, if serology is negative but the patient's symptoms are highly suggestive of CD, duodenal biopsy (with collection of at least 6 specimens) should be recommended. If the histological findings are suggestive of CD, a provisional diagnosis can be made and the patient started on a GFD. The clinical (and possibly histological) response to the diet should be assessed after an adequate period of time to confirm the diagnosis of CD (46) . In these cases, the presence of HLA-DQ2 and HLA-DQ8 alleles is merely an index of genetic predisposition to CD (47) .
In short, the diagnosis of CD has clearly increased over the past few decades, and it is now recognized as a common disorder. However, despite increased physician awareness and the availability of appropriate diagnostic methods, many cases of this disease still go undiagnosed, especially among the elderly. On the other hand, the frequency of unfounded diagnoses of CD is also on the rise. This reflects a tendency toward exclusively symptomatic diagnosis as well as the growing use of unvalidated tests for CD (e.g., the cytotoxic test, the sublingual or subcutaneous provocation/neutralization test) (48) (49) .
As a result, public healthcare spending is being increased in several countries (Italy included) by the growing number of prescriptions for GFDs.
In our opinion, the diagnosis of CD is a step-wise procedure that involves careful assessment of the following elements ( Fig. 1 When it is difficult to make a differential diagnosis, transmission ( Fig. 2A, B , C) and scanning ( Fig. 2D , E, F) electron microscopy studies may be useful (50) . Since the 1970's, these techniques have been used to demonstrate the presence of characteristic alterations involving the microvilli and cytoplasmic structures. Some of these alterations may still be observed after remission ofthe disease has been achieved with a GFD. Unfortunately, these studies are very expensive and require specially processed tissue specimens, so they are rarely used in clinical practice.
In conclusion, the diagnosis of CD is a complex process that requires the correct use of multiple clinical tools. In our opinion, serological markers are useful, but in patients who are seronegative, duodenal biopsy should be mandatory. Special care should be taken to ensure that the specimens collected are qualitatively and quantitatively appropriate, and the interpretation should be based on both clinical and histological elements. Clinical and histological responses to GFD therapy may be useful in such patients with symptoms suggestive of CD (51) .
